We were actually given the R and D reviews output last week. We will be going back to our membership to find out a little more about their perceptions of what they're recommending.
We are concerned, because when you start directing money toward specific companies again, you're picking the winners and losers, and we're always a little hesitant about whether that's going to be helpful or not. Then a lot of companies that may be using SR and ED effectively may no longer be able to access those funds.
We're not saying yes or no at this point. We want to go back to those who are currently using SR and ED and try to define better what it is, how they're using it, and whether the changes being suggested would be beneficial to them or not.